Anti-IL23α (Mirikizumab), Humanized Antibody

Anti-IL23α (Mirikizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23 but does not bind to IL12. IL-23 is expressed and secreted by dendritic cells and macrophages. It belongs to the family of IL-12 cytokines and has two subunits: p40 that is shared with IL-12 and p19 that is unique for IL-23. IL-23 plays a critical role in maintaining and expanding Th17 cells. It also stimulates multiple innate immune cells such as myeloid cells and NK cells to produce proinflammatory cytokines that play an important role in the pathogenesis of inflammatory diseases such as Ulcerative Colitis (UC). By binding to the p19 subunit of IL-23, the antibody inhibits the release of proinflammatory cytokines and reduces the inflammatory response. The original drug is currently undergoing clinical trials to treat moderate-to-severe UC, psoriasis, and Crohn’s disease

Immunogen Sequence:Human IL23α

Target Alternative Name:LY-3074828, LY3074828, P19, SGRF, IL-23, IL23A, IL23P19

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that targets IL-23 and inhibits the pathogenesis of chronic inflammatory diseases such as psoriasis

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.